Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors

Cancer Immunology, Immunotherapy

Volumn 51, Issue 3, 2002, Pages 153-162

  Lu, Yingjuan ^a,b   Low, Philip S ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b Endocyte Inc   (United States)

Author keywords

Cancer immunotherapy; Cytokine; Folate receptor; Folate targeted hapten; Humoral immune response

Indexed keywords

ALPHA INTERFERON; ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; FOLIC ACID; HAPTEN; INTERLEUKIN 2; RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; IMMUNOMODULATION; KIDNEY PROXIMAL TUBULE; LIFESPAN; LUNG CANCER; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; SUPPLEMENTATION; TARGET CELL; TREATMENT OUTCOME;

ANIMALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCEIN; FOLIC ACID; HAPTENS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-2; KINETICS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MODELS, CHEMICAL; NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036219732     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0266-6     Document Type: Article

References (42)

1. A comparison of commercially available adjuvants for use in research
2. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule
3. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy
4. Lymphokines and cytokines as cancer treatment. Immunotherapy realized
5. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells
6. Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma
7. Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer
8. Prospects for the therapeutic use of anticancer vaccines
9. Evidence for hapten recognition in receptor-mediated intracellular uptake of a hapten-protein conjugate by murine macrophage
10. Membrane receptors for endocytosis in the renal proximal tubule
11. Tumor escape from immune surveillance
12. An overview of cancer immunotherapy
13. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody
14. The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha
15. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines
16. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2
17. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies
18. Characterization of folate receptor from normal and neoplastic murine tissue: Influence of dietary folate on folate receptor expression
19. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines
20. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2
21. Chemo-immunotherapy of murine solid tumors: Enhanced therapeutic eFects by interleukin-2 combined with interferon alpha and the role of specific T cells
22. Adoptive T-cell immunotherapy of cancer
23. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis
24. Targeting of antihapten antibodies to activated T cells via an IL-2-hapten conjugate prolongs cardiac graft survival
25. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
26. Technology evaluation: Theratope, Biomira Inc
27. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: A National Biotherapy Study Group Trial
28. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines
29. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice
30. Folate-mediated targeting of therapeutic and imaging agents to cancers
31. Identification of human cancers deficient in antigen processing
32. DiFerential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications
33. Innate immune therapy for cancer. Screen for molecules capable of activating the innate immune system
34. Vaccination against human cancers
35. Targeted drug delivery via the folate receptor
36. Overexpression of folate binding protein in ovarian cancers
37. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha
38. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical
39. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues
40. Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis
41. Antibody-targeted immunotherapy for treatment of malignancy
42. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix